212141-54-3

Basic information

• Product Name: Vatalanib base
• Synonyms: N-(4-Chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)- 1-Phthalazinamine;1-PhthalazinaMine, N-(4-chlorophenyl)-4-(4-pyridinylMethyl)-;Vatalanib (PTK787) Dihydrochloride Base;Pynasunate, ZK222584, CGP-79787, PTK 787;(4-Chloro-phenyl)-(4-pyridin-4-ylmethyl-phthalazin-1-yl)-amine;Vatalanib (free base);VATALANIB
• CAS NO: 212141-54-3
• Molecular Formula: C₂₀H₁₅ClN₄
• Molecular Weight: 346.81
• Product Categories: Antineoplastic
• Mol File: 212141-54-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 209-212°
• Boiling Point: 587.8 °C at 760 mmHg
• Flash Point: 309.3 °C
• Appearance: /
• Density: 1.33 g/cm₃
• Vapor Pressure: 8.48E-14mmHg at 25°C
• Refractive Index: 1.711
• Storage Temp.: 2-8°C(protect from light)
• Solubility: ≥16.85 mg/mL in DMSO; ≥3.0125 mg/mL in EtOH with gentle warming and ultrasonic; ≥32.53 mg/mL in H2O with gentle warming and ultrasonic
• PKA: 5.46±0.10(Predicted)
• CAS DataBase Reference: Vatalanib base(CAS DataBase Reference)
• NIST Chemistry Reference: Vatalanib base(212141-54-3)
• EPA Substance Registry System: Vatalanib base(212141-54-3)

Safety Data

• Hazardous Substances Data: 212141-54-3(Hazardous Substances Data)

Usage

Uses

anti-viral

Definition

ChEBI: A member of the class of phthalazines that is phthalazine in which the hydrogens at positions 1 and 4have been replaced by a p-chlorophenylamino group and a pyridin-4-ylmethyl group, respectively. It is a multi-targeted tyrosine kinase inhibit r for all isoforms of VEGFR, PDGFR and c-Kit.

InChI:InChI=1/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)

Upstream product

• 67592-40-9 3-hydroxy-2-(pyridin-4-yl)-1H-inden-1-one 
• 91-15-6 phthalonitrile 
• 637-87-6 1-Chloro-4-iodobenzene 
• 106-39-8 bromochlorobenzene 
• 10445-91-7 4-(Chloromethyl)pyridine 
• 54751-01-8 4-(bromomethyl)pyridine 
• 106-47-8 4-chloro-aniline 
• 87-41-2 2-benzofuran-1(3H)-one 
• 107558-48-5 5-(pyridin-4-yl)methyl-2H-phthalazin-1-one 

Downstream Products

• 300843-20-3 ZK 228354 
• 300843-29-2 1-(4-Chlor-anilino)-4-(pyridin-4-yl-fluormethyl)-phthalazine 

Relevant articles and documents

Simple preparation method of vatalanib

The invention provides a simple preparation method of vatalanib. The method comprises the following steps: carrying out a Grignard reaction on 4-halomethylpyridine (III) and metallic magnesium to prepare a corresponding Grignard reagent, carrying out addition on the Grignard reagent and phthalonitrile, condensing the obtained addition product and hydrazine hydrate to prepare 1-amino-4-(pyridin-4-yl)methylpyridazine (IV), and carrying out a substitution reaction on the 1-amino-4-(pyridin-4-yl)methylpyridazine (IV) and 4-halochlorobenzene (V) to obtain the vatalanib (II). The method of the invention has the advantages of small amount of generated wastewater, small toxicity of the raw materials, safety, environmental friendliness, and high safety of the prepared vatalanib; and the finally prepared product has a high purity and a high yield.

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

Ocular therapy

A method for treating a subject suffering from epiretinal membrane formation or retinal detachment due to epiretinal membrane formation is disclosed. The method comprises administering a compound of the formula: wherein n is 0 to 2, R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl; and Z is unsubstituted or substituted pyridyl, an N-oxide thereof, wherein 1 or more N atoms carry an oxygen atom, or a salt thereof.